MAPT and Cognitive impairment: Finally, we used 18- to 22-month-old APP/PS1 mice that harbor human APPK670N/M671L and PSEN1ΔE9 mutations, without tau pathology (26), and, unlike 3xTg mice, display a less pronounced phenotype with overt cognitive impairment at about 12 months (26–28).